Scarica l'app Stockscreener
3.56
0.84%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.59
Aprire:
$3.59
Volume 24 ore:
1.97M
Relative Volume:
1.47
Capitalizzazione di mercato:
$615.30M
Reddito:
-
Utile/perdita netta:
$-54.70M
Rapporto P/E:
-10.79
EPS:
-0.33
Flusso di cassa netto:
$-51.36M
1 W Prestazione:
-4.30%
1M Prestazione:
+37.98%
6M Prestazione:
+36.92%
1 anno Prestazione:
-16.04%
Intervallo 1D:
$3.49
$3.675
Intervallo di 1 settimana:
$3.49
$3.9625
Portata 52W:
$1.89
$4.70
Savara Inc Stock (SVRA) Company Profile
Nome
Savara Inc
Settore
Industria
Telefono
51285113796
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Confronta SVRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
3.56 | 661.97M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-11-13 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-11-07 | Iniziato | Guggenheim | Buy |
| 2023-05-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2021-03-16 | Iniziato | Piper Sandler | Overweight |
| 2021-03-15 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-13 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Ripresa | ROTH Capital | Neutral |
| 2018-01-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-09-27 | Ripresa | ROTH Capital | Buy |
| 2017-09-22 | Iniziato | Jefferies | Buy |
| 2017-09-11 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Savara Inc Borsa (SVRA) Ultime notizie
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain OfficersSVRA - PR Newswire
Advanced analytics toolkit walkthrough for Savara Inc.Market Growth Review & Fast Exit and Entry Trade Guides - Newser
Signal strength of Savara Inc. stock in tech scannersQuarterly Trade Summary & Verified Short-Term Plans - Newser
Savara Increases Estimate of Autoimmune PAP Prevalence in U.S., Advances MOLBREEVI Toward FDA Resubmission - MSN
Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Levi & Korsinsky Moves to SueWallSt for Savara Inc. Investors That Lost Money - ACCESS Newswire
DOW Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Dow Inc. Class Action Lawsuit - GlobeNewswire Inc.
SVRA Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MarketScreener
SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - WV News
Savara Inc. Faces Legal Battle Over MOLBREEVI Controversy - TipRanks
Portnoy Law Firm Announces Class Action on Behalf of Savara, Inc. Investors - GlobeNewswire
SVRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Savara (NASDAQ:SVRA) Given New $11.00 Price Target at Guggenheim - MarketBeat
Important Notice to Long-Term Shareholders of Applied - GlobeNewswire
Exome Asset Management LLC Has $2.32 Million Position in Savara Inc. $SVRA - MarketBeat
HC Wainwright Issues Optimistic Estimate for Savara Earnings - MarketBeat
Savara Inc. (NASDAQ:SVRA) Receives $6.67 Consensus Target Price from Brokerages - Defense World
Savara Inc. Securities Lawsuit Investigation - Claim Depot
SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Savara (NASDAQ:SVRA) Price Target Raised to $8.00 at Oppenheimer - MarketBeat
SAVARA ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
Savara Inc. (SVRA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
Securities Fraud Investigation Into Savara Inc. (SVRA) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - Business Wire
SVRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - FinancialContent
SVRA ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Savara Inc. Investors - Business Wire
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Savara Inc. (SVRA) - Louisiana First News
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Guggenheim raises Savara stock price target to $11 on manufacturing updates - Investing.com
Investor Alert: Robbins LLP Informs Investors of the Savara Inc. Class Action Lawsuit - cnhinews.com
Oppenheimer Adjusts Savara Price Target to $8 From $6, Maintains Outperform Rating - MarketScreener
S P Trends: Is Savara Inc. impacted by rising ratesTrade Performance Summary & High Accuracy Swing Trade Signals - 뉴스영
Technical Models Suggest Savara Inc. May Rebound SoonJuly 2025 Recap & Verified Momentum Watchlists - beatles.ru
HC Wainwright Boosts Savara (NASDAQ:SVRA) Price Target to $8.00 - MarketBeat
Is Savara Inc. impacted by rising rates2025 Key Lessons & Weekly High Return Stock Forecasts - classian.co.kr
ADAR1 Capital Management LLC Has $3.77 Million Stock Position in Savara Inc. $SVRA - MarketBeat
Walleye Capital LLC Invests $574,000 in Savara Inc. $SVRA - MarketBeat
Trend analysis for Savara Inc. this weekShare Buyback & Daily Oversold Bounce Ideas - Newser
Nantahala Capital Management LLC Acquires 550,116 Shares of Savara Inc. $SVRA - MarketBeat
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
What are the risks of holding Savara Inc.July 2025 News Drivers & AI Enhanced Trade Execution Alerts - خودرو بانک
Regression analysis insights on Savara Inc. performanceJuly 2025 Breakouts & Weekly Setup with High ROI Potential - Newser
Can Savara Inc. grow without external fundingWeekly Market Outlook & AI Forecasted Entry/Exit Points - خودرو بانک
Nuveen LLC Makes New Investment in Savara Inc. $SVRA - MarketBeat
Is Savara Inc. subject to activist investor interestMarket Movers & Real-Time Stock Entry Alerts - خودرو بانک
Will Savara Inc. stock go up soonMarket Volume Report & Expert Curated Trade Setups - Newser
What high frequency data says about Savara Inc.Weekly Trend Summary & Consistent Growth Equity Picks - Newser
Savara Inc. to Present at Upcoming Healthcare Investor Conferences - MSN
H.C. Wainwright raises Savara stock price target to $8 on larger patient pool By Investing.com - Investing.com South Africa
Savara Inc. stock chart pattern explainedIPO Watch & Reliable Entry Point Alerts - Newser
Savara Inc Azioni (SVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Savara Inc Azioni (SVRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McCracken Joseph S | Director |
May 29 '25 |
Buy |
2.08 |
10,000 |
20,825 |
260,837 |
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):